Bendamustine Injection from Eagle Pharmaceuticals Renamed
June 3, 2019 – Eagle Pharmaceuticals has announced a new name for its bendamustine injection. The product, which previously was called bendamustine, will now be called Belrapzo™ (bendamustine hydrochloride injection).
The product first received U.S. FDA approval in May 2018 to treat chronic lymphocytic leukemia (CLL), as well as indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Although the active ingredient, bendamustine, is available as the primary active ingredient in other drug products, Belrapzo is a new formulation and not a generic. Recommended dosing is based on the indication, and should be modified in the event of treatment toxicity based on whether the toxicity is hematologic or non-hematologic in nature. Belrapzo is administered via intravenous infusion.